Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 24;9(5):e03973.
doi: 10.1002/ccr3.3973. eCollection 2021 May.

Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report

Quentin Dominique Thomas  1   2 , Léa Sinoquet  1 , Antonio Maraver  2 , Xavier Quantin  1   2
Affiliations
Case Reports

Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report

Quentin Dominique Thomas et al. Clin Case Rep. .

Abstract

We report the case of a patient with a complete metastatic adrenal response on Pembrolizumab for metastatic lung cancer. Treatment with a systemic corticosteroid-induced a time-dependent progression at his metastatic site. Surprisingly, after stopping the corticosteroid, we observed a new complete response in long-term adrenal metastases.

Keywords: case reports; immunotherapy; lung neoplasms; programmed cell death 1 receptor; tumor escape.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Evaluation of disease progression by CT scan at (A) Baseline scan before treatment with Pembrolizumab, (B) After 6 injections of Pembrolizumab, (C) After 22 injections of Pembrolizumab and the recent corticosteroid therapy, (D) After 24 injections of Pembrolizumab. Red arrows show the left adrenal gland
FIGURE 2
FIGURE 2
Maculopapular rash of the legs
FIGURE 3
FIGURE 3
Changes of the adrenal gland metastasis status over time. Cn, number of Pembrolizumab injections; M, month after NSCLC diagnosis. Blue rectangles depict the corticosteroid schedule
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646‐674. - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252‐264. - PMC - PubMed
    1. Reck M, Rodríguez‐Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med. 2016;375(19):1823‐1833. - PubMed
    1. Gandhi L, Rodríguez‐Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078‐2092. - PubMed
    1. Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncol Hematol. 2017;120:86‐92. - PubMed

Publication types

LinkOut - more resources